APLSApellis Pharmaceuticals, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-0.67

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$380,924

Balance Sheet

Total Assets

$57M

Total Liabilities

$33M

Stockholders' Equity

$24M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$12M	-$7M	-81.5%
Net Income	-$12M	-$7M	-82.4%

APLS Q2 2017 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena